OSI Board Rejects Astellas $3.5B Bid

Law360, New York (March 15, 2010, 3:02 PM EDT) -- The board of OSI Pharmaceuticals Inc. has rejected a $3.5 billion hostile takeover bid from a unit of Japanese pharmaceutical giant Astellas Pharma Inc., instead putting out feelers for other suitors.

New York-based OSI said Monday that its board of directors was unanimously recommending that OSI shareholders reject the offer and not tender their shares. Astellas US Holding Inc., a wholly owned subsidiary of Astellas Pharma Inc., said March 1 that it planned to commence a tender offer to acquire all of OSI's outstanding shares for...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.